Lars H.P. Murrer

IN VIVO DOSIMETRY USING A LINEAR MOSFET-ARRAY DOSIMETER TO DETERMINE THE URETHRA DOSE IN 125I PERMANENT PROSTATE IMPLANTS

PURPOSE In vivo dosimetry during brachytherapy of the prostate with (125)I seeds is challenging because of the high dose gradients and low photon energies involved. We present the results of a study using metal-oxide-semiconductor field-effect transistor (MOSFET) dosimeters to evaluate the dose in the urethra after a permanent prostate implantation procedure. METHODS AND MATERIALS Phantom measurements were made to validate the measurement technique, determine the measurement accuracy, and define action levels for clinical measurements. Patient measurements were performed with a MOSFET array in the urinary catheter immediately after the implantation procedure. A CT scan was performed, and dose values, calculated by the treatment planning system, were compared to in vivo dose values measured with MOSFET dosimeters. RESULTS Corrections for temperature dependence of the MOSFET array response and photon attenuation in the catheter on the in vivo dose values are necessary. The overall uncertainty in the measurement procedure, determined in a simulation experiment, is 8.0% (1 SD). In vivo dose values were obtained for 17 patients. In the high-dose region (> 100 Gy), calculated and measured dose values agreed within 1.7% +/- 10.7% (1 SD). In the low-dose region outside the prostate (< 100 Gy), larger deviations occurred. CONCLUSIONS MOSFET detectors are suitable for in vivo dosimetry during (125)I brachytherapy of prostate cancer. An action level of +/- 16% (2 SD) for detection of errors in the implantation procedure is achievable after validation of the detector system and measurement conditions.

Forward Intensity-Modulated Radiotherapy Planning in Breast Cancer to Improve Dose Homogeneity: Feasibility of Class Solutions

PURPOSE To explore forward planning methods for breast cancer treatment to obtain homogeneous dose distributions (using International Commission on Radiation Units and Measurements criteria) within normal tissue constraints and to determine the feasibility of class solutions. METHODS AND MATERIALS Treatment plans were optimized in a stepwise procedure for 60 patients referred for postlumpectomy irradiation using strict dose constraints: planning target volume (PTV)(95%) of >99%; V(107%) of <1.8 cc; heart V(5 Gy) of <10% and V(10 Gy) of <5%; and mean lung dose of <7 Gy. Treatment planning started with classic tangential beams. Optimization was done by adding a maximum of four segments before adding beams, in a second step. A breath-hold technique was used for heart sparing if necessary. RESULTS Dose constraints were met for all 60 patients. The classic tangential beam setup was not sufficient for any of the patients; in one-third of patients, additional segments were required (<3), and in two-thirds of patients, additional beams (<2) were required. Logistic regression analyses revealed central breast diameter (CD) and central lung distance as independent predictors for transition from additional segments to additional beams, with a CD cut-off point at 23.6 cm. CONCLUSIONS Treatment plans fulfilling strict dose homogeneity criteria and normal tissue constraints could be obtained for all patients by stepwise dose intensity modification using limited numbers of segments and additional beams. In patients with a CD of >23.6 cm, additional beams were always required.

In Vivo Dosimetry With a Linear MOSFET Array to Evaluate the Urethra Dose During Permanent Implant Brachytherapy Using Iodine-125

PURPOSE To develop a technique to monitor the dose rate in the urethra during permanent implant brachytherapy using a linear MOSFET array, with sufficient accuracy and without significantly extending the implantation time. METHODS AND MATERIALS Phantom measurements were performed to determine the optimal conditions for clinical measurements. In vivo measurements were performed in 5 patients during the (125)I brachytherapy implant procedure. To evaluate if the urethra dose obtained in the operating room with the ultrasound transducer in the rectum and the patient in treatment position is a reference for the total accumulated dose; additional measurements were performed after the implantation procedure, in the recovery room. RESULTS In vivo measurements during and after the implantation procedure agree very well, illustrating that the ultrasound transducer in the rectum and patient positioning do not influence the measured dose in the urethra. In vivo dose values obtained during the implantation are therefore representative for the total accumulated dose in the urethra. In 5 patients, the dose rates during and after the implantation were below the maximum dose rate of the urethra, using the planned seed distribution. CONCLUSION In vivo dosimetry during the implantation, using a MOSFET array, is a feasible technique to evaluate the dose in the urethra during the implantation of (125)I seeds for prostate brachytherapy.

Use of skin markers and electronic portal imaging to improve verification of tangential breast irradiation

We investigated the added value of skin markers in 566 electronic portal images (EPIs) in 48 breast cancer patients treated with tangential fields. EPIs were matched to the corresponding DRRs using skin markers, anatomy, or a combination of both. Skin markers improved determination of setup errors in cranio-caudal direction.

Dose reduction in LDR brachytherapy by implanted prostate gold fiducial markers.

PURPOSE The dosimetric impact of gold fiducial markers (FM) implanted prior to external beam radiotherapy of prostate cancer on low dose rate (LDR) brachytherapy seed implants performed in the context of combined therapy was investigated. METHODS A virtual water phantom was designed containing a single FM. Single and multi source scenarios were investigated by performing Monte Carlo dose calculations, along with the influence of varying orientation and distance of the FM with respect to the sources. Three prostate cancer patients treated with LDR brachytherapy for a recurrence following external beam radiotherapy with implanted FM were studied as surrogate cases to combined therapy. FM and brachytherapy seeds were identified on post implant CT scans and Monte Carlo dose calculations were performed with and without FM. The dosimetric impact of the FM was evaluated by quantifying the amplitude of dose shadows and the volume of cold spots. D(90) was reported based on the post implant CT prostate contour. RESULTS Large shadows are observed in the single source-FM scenarios. As expected from geometric considerations, the shadows are dependent on source-FM distance and orientation. Large dose reductions are observed at the distal side of FM, while at the proximal side a dose enhancement is observed. In multisource scenarios, the importance of shadows appears mitigated, although FM at the periphery of the seed distribution caused underdosage (<prescription dose). In clinical cases, the FM reduced the dose to some voxels by up to 50% and generated shadows with extents of the order of 4 mm. Within the prostate contour, cold spots (<95% prescription dose) of the order of 20 mm(3) were observed. D(90) proved insensitive to the presence of FM for the cases selected. CONCLUSIONS There is a major local impact of FM present in LDR brachytherapy seed implant dose distributions. Therefore, reduced tumor control could be expected from FM implanted in tumors, although our results are too limited to draw conclusions regarding clinical significance.

Evaluation of three different CT simulation and planning procedures for the preoperative irradiation of operable rectal cancer.

PURPOSE To find the best procedure regarding quality and work load for treatment planning in operable non-locally advanced rectal cancer using 3D CT-based information. METHODS The study population consisted of 62 patients with non-locally advanced tumours, as defined by MRI in the lower (N=16), middle (N=25) and upper (N=21) rectum referred for preoperative short-course radiotherapy. In procedure 1 (Pr1), planning in one central plane was performed (field borders/shielding based on bony anatomy). In procedure 2 (Pr2), field borders were determined by 2 markers for the extension of the CTV in the cranial and ventral direction. Dose optimization was performed in one central and two border planes. In procedure 3(Pr3) the PTV volume (CTV was contoured on CT) received conformal treatment (3D dose optimization). RESULTS Conformity index reached 1.6 for Pr3 vs. 2.2 for Pr2 (p<0.001). PTV coverage was 87%, 94%, 99% in Pr1, Pr2, Pr3, respectively (p=0.001). In Pr2 target coverage was below 95% for low/middle tumours. PTV coverage was reduced by narrow field borders (18-23%) and shielding (28%). A total of 43.5% (1-100) of the bladder volume was treated in Pr2 in contrast to 16% (0-68) in Pr3 (p<0.001). The maximum dose was exceeded in 10 patients (26-298 cc) and 2 patients (21-36 cc) in procedures 1 and 2, respectively. The overall time spent by technologists was 86 min for Pr3 vs 17 min in Pr2 and Pr1 (p<0.001), for radiation oncologists this difference was 24 vs 4 min (p<0.001). CONCLUSIONS Pr1 does not fulfill todays quality requirements. Pr3 provides the best quality at the cost of working time. Pr2 is less time consuming, however, the PTV coverage was insufficient, with also much larger treatment volumes. An optimization of the PTV coverage in Pr2 even further enlarged the treatment volume.

Actual target coverage after setup verification using surgical clips compared with external skin markers in postoperative breast cancer radiation therapy

PURPOSE After changing from offline setup verification to online setup verification using external skin markers in breast cancer patients, we noticed an increase in localized acute skin toxicity beneath the markers. Also, in vivo 3-dimensional dose measurements showed deviations between the delivered and the planned dose distributions; therefore, we investigated the accuracy of setup verification using surgical clips in the tumor bed, with a focus on target coverage of whole breast and tumor bed. METHODS AND MATERIALS Orthogonal kilovoltage images were acquired before every fraction in 35 breast cancer patients, deriving an online 3-dimensional setup error by matching on external skin markers. In retrospect, a rematch was performed using surgical clips. For 155 fractions (ie, 5-6 fractions/patient), a cone beam computed tomography (CT) scan was available. Analysis concerned: (1) visibility of the clips, (2) migration of the clips, (3) comparison of setup errors according to both match methods, and (4) comparison of target coverage by recalculating the dose on the online setup-corrected cone beam CT scan with the patient setup according to both match methods. External validation of the surgical clip-based online setup verification was performed in 23 patients by analyzing kilovoltage images of 100 fractions, obtained after treatment. RESULTS All types of surgical clips could be visualized. The clip to center-of-mass distance decreased on average by 2 mm (standard deviation, 1) over the course of treatment. Setup differences between match methods were on average <0.5 mm in all directions. The reconstructed dose distributions showed standard deviations of volumes receiving 95% or 107% of prescribed dose and mean dose of the breast and boost planning target volume were similar for the planning CT and the cone beam CTs, for both match procedures. An external validation in 23 patients showed reassuring setup errors <2 mm. CONCLUSIONS Online setup verification using surgical clips results in comparable setup corrections and target volume coverage as verification using skin markers. By omitting skin markers acute skin toxicity beneath the markers is prevented.

Three-dimensional dose evaluation in breast cancer patients to define decision criteria for adaptive radiotherapy

Abstract Background: Dose-guided adaptive radiation therapy (DGART) is the systematic evaluation and adaptation of the dose delivery during treatment for an individual patient. The aim of this study is to define quantitative action levels for DGART by evaluating changes in 3D dose metrics in breast cancer and correlate them with clinical expert evaluation. Material and methods: Twenty-three breast cancer treatment plans were evaluated, that were clinically adapted based on institutional IGRT guidelines. Reasons for adaptation were variation in seroma, hematoma, edema, positioning or problems using voluntary deep inspiration breath hold. Sixteen patients received a uniform dose to the breast (clinical target volume 1; CTV1). Six patients were treated with a simultaneous integrated boost to CTV2. The original plan was copied to the CT during treatment (re-CT) or to the stitched cone-beam CT (CBCT). Clinical expert evaluation of the re-calculated dose distribution and extraction of dose-volume histogram (DVH) parameters were performed. The extreme scenarios were evaluated, assuming all treatment fractions were given to the original planning CT (pCT), re-CT or CBCT. Reported results are mean ± SD. Results: DVH results showed a mean dose (Dmean) difference between pCT and re-CT of -0.4 ± 1.4% (CTV1) and −1.4 ± 2.1% (CTV2). The difference in V95% was −2.6 ± 4.4% (CTV1) and −9.8 ± 8.3% (CTV2). Clinical evaluation and DVH evaluation resulted in a recommended adaptation in 17/23 or 16/23 plans, respectively. Applying thresholds on the DVH parameters: Dmean CTV, V95% CTV, Dmax, mean lung dose, volume exceeding 107% (uniform dose) or 90% (SIB) of the prescribed dose enabled the identification of patients with an assumed clinically relevant dose difference, with a sensitivity of 0.89 and specificity of 1.0. Re-calculation on CBCT imaging identified the same plans for adaptation as re-CT imaging. Conclusions: Clinical expert evaluation can be related to quantitative DVH parameters on re-CT or CBCT imaging to select patients for DGART.